Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid Cancers

NCT05733000 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT05733000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05733000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid Cancers
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Recruiting
Start date
March 8, 2023
Completion date
March 4, 2030
Enrollment
94 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced biliary tract carcinoma, advanced colorectal carcinoma, advanced gastroesophageal junction adenocarcinoma, advanced lung adenocarcinoma, advanced malignant solid neoplasm, advanced ovarian carcinoma, advanced pancreatic carcinoma, advanced urothelial carcinoma, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iv gastroesophageal junction adenocarcinoma ajcc v8, metastatic biliary tract carcinoma, metastatic colorectal carcinoma, metastatic gastroesophageal junction adenocarcinoma, metastatic lung adenocarcinoma, metastatic ovarian carcinoma, metastatic pancreatic carcinoma, metastatic urothelial carcinoma, refractory biliary tract carcinoma, refractory colorectal carcinoma, refractory gastroesophageal junction adenocarcinoma, refractory lung adenocarcinoma, refractory ovarian carcinoma, refractory pancreatic carcinoma, refractory urothelial carcinoma, stage ii pancreatic cancer ajcc v8, stage iii colorectal cancer ajcc v8, stage iii lung cancer ajcc v8, stage iii ovarian cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iv colorectal cancer ajcc v8, stage iv lung cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iv pancreatic cancer ajcc v8